申请人:Lilly Industries Limited
公开号:US04281017A1
公开(公告)日:1981-07-28
Compounds of formula I ##STR1## wherein either R.sup.1 and R.sup.2 are both hydrogen or R.sup.1 and R.sup.2, taken together, represent a group of formula (a): ##STR2## in which R.sup.5 is hydrogen, halogen or C.sub.1-4 alkyl, R.sup.3 is hydrogen or a group of formula (b): ##STR3## in which R.sup.6 is hydrogen or C.sub.1-4 alkyl, and R.sup.4 is hydrogen or a group of formula --CHR.sup.7 COOH, where R.sup.7 is hydrogen or C.sub.1-4 alkyl, provided that: (i) when R.sup.3 is a group of formula (b), then R.sup.1, R.sup.2 and R.sup.4 are all hydrogen, (ii) when R.sup.3 is hydrogen, then R.sub.4 is --CHR.sup.7 COOH, and (iii) when R.sup.1 and R.sup.2, together, represent a group of formula (a), then R.sub.3 is hydrogen; possess pharmacological activity, in particular anti-inflammatory activity and are particularly useful in treatment of rheumatoid arthritis.
式I的化合物,其中R.sup.1和R.sup.2都是氢或R.sup.1和R.sup.2在一起表示为式(a)的基团:##STR2## 其中R.sup.5是氢,卤素或C.sub.1-4烷基,R.sup.3是氢或式(b)的基团:##STR3## 其中R.sup.6是氢或C.sub.1-4烷基,R.sup.4是氢或式--CHR.sup.7 COOH的基团,其中R.sup.7是氢或C.sub.1-4烷基,前提是:(i)当R.sup.3是式(b)的基团时,R.sup.1、R.sup.2和R.sup.4都是氢,(ii)当R.sup.3是氢时,R.sub.4是--CHR.sup.7 COOH,(iii)当R.sup.1和R.sup.2在一起表示为式(a)的基团时,R.sub.3是氢;具有药理活性,特别是抗炎活性,并且在治疗类风湿性关节炎方面特别有用。